Who are BAY 86-7660,levomefolate calcium's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PEMETREXED DIPOTASSIUM, Fusilev, Fusilev, Alimta, Wellcovorin, Leucovorin/levofolinate calcium.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bay-86-7660-levomefolate-calcium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

BAY 86-7660,levomefolate calcium — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BAY 86-7660,levomefolate calcium (BAY 86-7660,levomefolate calcium) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Folate analog. Area: Oncology.

phase 1 Folate analog Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BAY 86-7660,levomefolate calcium (BAY 86-7660,levomefolate calcium) — Bayer. Levomefolate calcium is a folate analog that acts as a methyl donor in one-carbon metabolism.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BAY 86-7660,levomefolate calcium TARGET	BAY 86-7660,levomefolate calcium	Bayer	phase 1	Folate analog
PEMETREXED DIPOTASSIUM	PEMETREXED DIPOTASSIUM		marketed	Folate Analog Metabolic Inhibitor [EPC]		2024-01-01
Fusilev	Levofolinic acid	Spectrum Pharms	marketed	Folate Analog		2008-01-01
Fusilev	levoleucovorin	Acrotech Biopharma	marketed	Folate Analog		2008-01-01
Alimta	pemetrexed	Actavis	marketed	Folate Analog Metabolic Inhibitor	Folate receptor alpha	2004-01-01
Wellcovorin	leucovorin	Pfizer Japan Inc	marketed	Folate Analog	Dihydrofolate reductase	1952-01-01
Leucovorin/levofolinate calcium	Leucovorin/levofolinate calcium	Merck Sharp & Dohme LLC	phase 3	Folate analog; chemotherapy adjuvant	Thymidylate synthase (indirect); folate metabolism

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2035-10-28 — Alimta · 9604990 · Compound · US
2036-02-19 — Alimta · 12115164 · Method of Use · US
2036-02-19 — Alimta · 11793813 · Formulation · US
2039-03-25 — Fusilev · 11541012 · US

Sponsor landscape (Folate analog class)

Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BAY 86-7660,levomefolate calcium — Competitive Intelligence Brief. https://druglandscape.com/ci/bay-86-7660-levomefolate-calcium. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab